Novartis reported $215M in Interest Expense on Debt for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Alcon AG ALC:SW USD 34M 3M
Amgen AMGN:US USD 368M 40M
Biogen BIIB:US USD 59.9M 5.9M
Bristol Myers Squibb BMY:US USD 299M 14M
Eli Lilly And LLY:US USD 81.5M 300K
Fresenius Medical Care FME:GR EUR 92M 7M
Genmab GEN:DC DKK 6M 0
Gilead Sciences GILD:US USD 229M 13M
Lonza Group LONN:SW CHF 28M 2M
Novartis NOVN:VX USD 215M 13M
Novartis NVS:US USD 215M 13M
Pfizer PFE:US USD 311M 18M
Recordati REC:IM EUR 7.48M 1.16M
Regeneron Pharmaceuticals REGN:US USD 15.3M 2.2M